Vyant Bio (OTCMKTS:VYNT) is a preclinical contract research organization that specializes in human biology–based platforms for drug discovery and translational research. The company develops and provides phenotypic assays and functional models using primary human tissues, induced pluripotent stem cell–derived cells, and ex vivo organotypic systems. These offerings are designed to enhance target validation, lead optimization and safety assessment by delivering higher biological relevance compared to traditional in vitro screening methods.
Through its proprietary library of human cell and tissue models, Vyant Bio offers services that include high-content imaging, functional phenotypic screening, electrophysiological assays and bioinformatics-driven data analytics. The company’s technology supports research in areas such as neuroscience, cardiovascular disorders, immuno-oncology and metabolic disease, helping clients generate translational insights earlier in the drug development process and potentially reducing preclinical attrition.
Headquartered in Atlanta, Georgia, Vyant Bio operates laboratories equipped with advanced automation and imaging infrastructure and collaborates with academic and industry partners. The company serves pharmaceutical and biotechnology clients across North America and Europe, providing end‐to‐end study design, execution and data interpretation tailored to the specific needs of each drug discovery program.
Vyant Bio’s leadership team brings together expertise in molecular biology, pharmacology and high-throughput screening to steer scientific strategy and platform development. The company continues to expand its human biology offerings with the goal of addressing critical challenges in preclinical translational research.
AI Generated. May Contain Errors.
Free VYNT Stock Alerts